Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib Plus HAIC Versus Sorafenib for HCC With Major PVTT
NCT03009461Phase 2Completed
- Sponsor
- Peking University
- Start
- Jun 2017
- Primary completion
- Jun 2020
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin, fluorouracil in hepatocellular carcinoma (HCC), portal vein tumor thrombosis (PVTT), sponsored by Peking University. Started Jun 2017; status: completed.
02
Drugs
oxaliplatinfluorouracil
03
Conditions
hepatocellular carcinoma (HCC)portal vein tumor thrombosis (PVTT)
Beyond the preview
Go deeper on NCT03009461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03009461.